Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 7 studies

@CovidAnalysis, December 2025, Version 22V22
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ansarin (RCT) 91% 0.09 [0.01-1.59] 24mg death 0/39 5/39 Improvement, RR [CI] Dose (1d) Treatment Control Ansarin (RCT) 89% 0.11 [0.01-0.84] 24mg ventilation 1/39 9/39 Ansarin (RCT) 82% 0.18 [0.04-0.77] 24mg ICU 2/39 11/39 Vila Méndez (RCT) 67% 0.33 [0.01-7.94] 48mg oxygen 0/98 1/93 Vila Méndez (RCT) 67% 0.33 [0.01-7.94] 48mg hosp. 0/98 1/93 Vila Méndez (RCT) 71% 0.29 [0.03-2.68] 48mg no recov. 1/52 3/45 Vila Méndez (RCT) -187% 2.87 [0.12-68.6] 48mg no recov. 1/52 0/45 Vila Méndez (RCT) -7% 1.07 [0.64-1.77] 48mg viral load 98 (n) 93 (n) Vila Méndez (RCT) 17% 0.83 [0.41-1.66] 48mg viral load 98 (n) 93 (n) Vila Méndez (RCT) -41% 1.41 [0.71-2.80] 48mg viral load 98 (n) 93 (n) Vila Méndez (RCT) 13% 0.87 [0.68-1.11] 48mg viral+ 52/98 57/93 Vila Méndez (RCT) -14% 1.14 [0.94-1.37] 48mg viral+ 73/98 61/93 Li (RCT) 75% 0.25 [0.05-1.35] 96mg no disch. 2/12 4/6 Li (RCT) 50% 0.50 [0.09-2.73] 96mg oxygen 2/12 2/6 Mareev (RCT) 11% 0.89 [0.65-1.22] 32mg no recov. 33 (n) 33 (n) CT​1​ Mareev (RCT) 39% 0.61 [0.14-0.97] 32mg no recov. 14/24 20/21 CT​1​ Mareev (RCT) 8% 0.92 [0.77-1.09] 32mg hosp. time 33 (n) 33 (n) CT​1​ Mareev (RCT) 87% 0.13 [0.01-2.25] 32mg viral+ 0/17 3/13 CT​1​ Tolouian (RCT) 76% 0.24 [0.01-8.03] 32mg death 48 (n) 52 (n) Tolouian (RCT) 76% 0.24 [0.01-7.69] 32mg no improv. 48 (n) 52 (n) Tolouian (RCT) -75% 1.75 [1.13-2.71] 32mg viral+ 29/48 18/52 Mikhaylov (RCT) 80% 0.20 [0.01-3.97] 24mg hosp. 0/25 2/25 Mikhaylov (RCT) 91% 0.09 [0.01-1.56] 24mg symp. case 0/25 5/25 Mikhaylov (RCT) 71% 0.29 [0.07-1.24] 24mg cases 2/25 7/25 Tolouian (DB RCT) 33% 0.67 [0.04-10.5] 24mg death 0/187 1/185 Tolouian (DB RCT) 70% 0.30 [0.05-1.78] 24mg hosp. 1/187 6/185 Tolouian (DB RCT) 53% 0.47 [0.25-0.87] 24mg symp. case 16/187 34/185 Tolouian (DB RCT) 50% 0.50 [0.24-0.99] 24mg cases 13/187 26/185 Bromhexine COVID-19 outcomes c19early.org December 2025 ​1​ CT: study uses combined treatment Favors bromhexine Favors control
Fig. S1. All outcomes.